Mga Batayang Estadistika
| CIK | 1119643 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nutra Pharma Corp.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| September 3, 2025 |
EXHIBIT 16.1 September 3, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Nutra Pharma Corp. under Item 4.01 of its Form 8-K dated September 3, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Nutra Pharma Corp contained t |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2024 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission File |
|
| March 22, 2024 |
Exhibit 99.2 RIK J DEITSCH 6400 Park of Commerce Blvd ♦ Suite 1B Boca Raton, FL 33487 Office (954) 509-0911 ♦ Fax (866) 744-3655 March 19, 2024 Board of Directors Nutra Pharma Corporation Members of the Board: Pursuant to my settlement with the Securities and Exchange Commission (SEC) I am resigning as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer of Nutra P |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 22, 2024 |
Nutra Pharma Corp. Reaches Settlement with SEC Exhibit 99.1 Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647 [email protected] Nutra Pharma Corp. Reaches Settlement with SEC Nutra Pharma Corp. has reached a bifurcated settlement with the SEC along with its CEO and a Consultant to the company. March 22, 2024 - Coral Springs, Florida - Nutra Pharma Corporation (OTC: NPHC), (“Nutra Pharma” or the “Company”) reached a settlement with the U |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? For Period Ended: September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Tra |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transiti |
|
| August 4, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2022 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2022 |
Letter of Rotenberg dated August 4, 2022 to the SEC regarding statements included in this Form 8-K. Exhibit 16.1 |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? For Period Ended: March 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transit |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transi |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement NUTRA PHARMA CORP. (Name of Registra |
|
| January 14, 2022 |
NPHC / Nutra Pharma Corp. / Deitsch Rik J Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Nutra Pharma Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 67060U208 (CUSIP Number) Rik J. Deitsch 1537 NW 65th Avenue Plantation, Florida 33313 954-509-0911 (Name, Address and Telephone Number of Person Authorized to Receive Notices |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement NUTRA PHARMA CORP. (Name of Registra |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| September 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000?32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000?32141 NUTRA PHARMA CORP. (Name of registrant |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000?32141 NUTRA PHARMA CORP. (Name of registrant |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000?32141 NUTRA PHARMA CORP. (Name of registrant |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000?32141 NUTRA PHARMA CORP. (Name of regist |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000?32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000?32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| April 1, 2019 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form N-SAR For Period Ended: December 31, 2018 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N |
|
| November 19, 2018 |
NPHC / Nutra Pharma Corp. FORM 10-Q (Quarterly Report) 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000–32141 NUTRA PHARMA CORP. (Name of regis |
|
| November 14, 2018 |
NPHC / Nutra Pharma Corp. FORM NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: September 30, 2018 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on F |
|
| October 9, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2018 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission |
|
| October 9, 2018 |
Exhibit 16.1 Exhibit 16.1 October 9, 2018 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 RE: Nutra Pharma Corp. Changes in Registrant’s Certifying Accountant We have read the statements of Nutra Pharma Corp., pertaining to our firm included under Item 4.01 of Form 8-K dated October 9, 2018 and agree with such statements as they pertain to our firm. We have read Item 4. |
|
| September 28, 2018 |
Nutra Pharma Comments on SEC Complaint Exhibit 99.1 Exhibit 99.1 Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647 [email protected] Nutra Pharma Comments on SEC Complaint Nutra Pharma is providing comments on the SEC Complaint filed against Nutra Pharma, its CEO and a Consultant to the company. September 28, 2018 - Coral Springs, Florida - Nutra Pharma Corporation (OTC: NPHC), provided the following comment on the lawsuit filed |
|
| September 28, 2018 |
Regulation FD Disclosure, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2018 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commiss |
|
| August 17, 2018 |
NPHC / Nutra Pharma Corp. FORM 10-Q (Quarterly Report) 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000–32141 NUTRA PHARMA CORP. (Name of registrant |
|
| August 14, 2018 |
NPHC / Nutra Pharma Corp. FORM NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: June 30, 2018 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N |
|
| June 29, 2018 |
NPHC / Nutra Pharma Corp. / Deitsch Rik J - SCHEDULE 13D Activist Investment 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )* NUTRA PHARMA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 67060U208 (CUSIP Number) Rik J. Deitsch 12538 W. Atlantic Blvd. Coral Springs, FL 33071 (954) 509- |
|
| June 6, 2018 |
NPHC / Nutra Pharma Corp. / Lake Shore Advisors Llc - SCHEDULE 13D Activist Investment 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )* NUTRA PHARMA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 6706OU208 (CUSIP Number) David Wittlinger Lake Shore Advisors, LLC 229 Shore Drive East Lake, OH 4 |
|
| May 21, 2018 |
NPHC / Nutra Pharma Corp. FORM 10-Q (Quarterly Report) 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000–32141 NUTRA PHARMA CORP. (Name of registran |
|
| May 15, 2018 |
NPHC / Nutra Pharma Corp. FORM NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: March 31, 2018 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form |
|
| April 17, 2018 |
NPHC / Nutra Pharma Corp. FORM 10-K (Annual Report) 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact |
|
| April 2, 2018 |
NPHC / Nutra Pharma Corp. NT 10-K NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form N-SAR For Period Ended: December 31, 2017 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N |
|
| March 20, 2018 |
NPHC / Nutra Pharma Corp. DEF 14C Schedule 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: [ ] Preliminary information statement [ ] Confidential, for use of the Commission only (as permitted |
|
| March 8, 2018 |
NPHC / Nutra Pharma Corp. PRE 14C Schedule 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: [X] Preliminary information statement [ ] Confidential, for use of the Commission only (as permitted |
|
| March 7, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2018 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commissi |
|
| February 5, 2018 |
NPHC / Nutra Pharma Corp. / Coventry Enterprises,llc - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) Nutra Pharma Corp. (Name of Issuer) common stock (Title of Class of Securities) 67060U208 (CUSIP Number) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remaind |
|
| February 2, 2018 |
NPHC / Nutra Pharma Corp. / Coventry Enterprises,llc - SCHEDULE13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Nutra Pharma Corp. (Name of Issuer) common stock (Title of Class of Securities) 67060U208 (CUSIP Number) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainde |
|
| November 20, 2017 |
NPHC / Nutra Pharma Corp. FORM 10-Q (Quarterly Report) 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10–Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000–32141 NUTRA PHARMA CORP. (Name of regis |
|
| November 14, 2017 |
NPHC / Nutra Pharma Corp. FORM NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: September 30, 2017 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on F |
|
| November 3, 2017 |
CERTIFICATE OF DETERMINATION OF PREFERENCES SERIES A PREFERRED STOCK NUTRA PHARMA CORP. Exhibit 3.1 Exhibit 3.1 CERTIFICATE OF DETERMINATION OF PREFERENCES OF SERIES A PREFERRED STOCK OF NUTRA PHARMA CORP. The undersigned, Rik J. Deitsch and Nina Goldstein, President and Secretary, respectively, of Nutra Pharma Corp., a California corporation, do hereby certify: FIRST: The Articles of Incorporation of the Corporation authorize the issuance of 20,000,000 shares of stock designated ?pr |
|
| November 3, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2017 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commissio |
|
| August 14, 2017 |
NPHC / Nutra Pharma Corp. FORM 10-Q (Quarterly Report) 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000–32141 NUTRA PHARMA CORP. (Name of registrant |
|
| May 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registran |
|
| May 15, 2017 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: March 31, 2017 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form |
|
| May 4, 2017 |
Exhibit Exhibit 16.1 432 Park Avenue South, 10th Floor New York , NY 10016 / (212) 481-3490 1901 South Congress Avenue, Suite 110 Boynton Beach, FL 33426 / (561) 752-1721 May 1, 2017 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 RE: Nutra Pharma Corp. File Ref No: 000-32141 We have read the statements of Nutra Pharma Corp., pertaining to our firm included under Item 4 |
|
| May 4, 2017 |
Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2017 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact |
|
| March 31, 2017 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form N-SAR For Period Ended: December 31, 2016 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N |
|
| November 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| November 15, 2016 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: September 30, 2016 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on F |
|
| August 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| August 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| August 15, 2016 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: June 30, 2016 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N |
|
| August 15, 2016 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: June 30, 2016 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N |
|
| July 26, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 21, 2016 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission F |
|
| June 21, 2016 |
10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CO |
|
| May 27, 2016 |
Nutra Pharma (Quarterly Report) 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registran |
|
| May 17, 2016 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [X] For Period Ended: March 31, 2016 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form |
|
| April 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact |
|
| March 30, 2016 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form N-SAR For Period Ended: December 31, 2015 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N |
|
| November 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| November 17, 2015 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 12b-25 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10D ? Form N-SAR ? Form N-CSR x For Period Ended: September 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on F |
|
| August 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| August 17, 2015 |
NT 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10D ? Form N-SAR ? Form N-CSR x For Period Ended: June 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For |
|
| May 19, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| May 18, 2015 |
NT 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10D ? Form N-SAR ? Form N-CSR x For Period Ended: March 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For |
|
| April 29, 2015 |
CERTIFICATE OF AMENDMENT TO THE ARTICLES OF INCORPORATION NUTRA PHARMA CORP. Exhibit Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF NUTRA PHARMA CORP. The undersigned hereby certify that: 1. They are the Chief Executive Officer and the Secretary, respectively, of NUTRA PHARMA CORP., a California corporation (the ?Corporation?). 2. Article FIFTH is deleted in its entirety and replaced with the following (the ?Amendment?): ?This corporation is autho |
|
| April 29, 2015 |
8-K 1 a12743.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2015 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) |
|
| April 21, 2015 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2015 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission |
|
| April 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| April 1, 2015 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form N-SAR For Period Ended: December 31, 2014 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N |
|
| March 17, 2015 |
PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a party other than the registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Pursuant Rule 14a-12 NUTRA PHARMA CORP. |
|
| March 3, 2015 |
NPHC / Nutra Pharma Corp. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a party other than the registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Pursuant Rule 14a-12 NUTRA PHARMA CORP. |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| August 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A AMENDMENT NO. 1 (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| May 20, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| May 16, 2014 |
NT 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10D ¨ Form N-SAR ¨ Form N-CSR x For Period Ended: March 31, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For |
|
| March 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| November 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2013 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| November 18, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10D ¨ Form N-SAR ¨ Form N-CSR x For Period Ended: September 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the |
|
| September 25, 2013 |
12502 West Atlantic Blvd ¨ Coral Springs, Florida 33071 Office (954) 509-0911 ¨ Fax (877) 895-5647 12502 West Atlantic Blvd ¨ Coral Springs, Florida 33071 Office (954) 509-0911 ¨ Fax (877) 895-5647 September 25, 2013 Dear Fellow Shareholders of Nutra Pharma: I wanted to take this opportunity to update you on the status of the Company and briefly outline our goals and expectations for the coming months. |
|
| September 25, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 25, 2013 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission |
|
| September 25, 2013 |
Nutra Pharma Letter to Shareholders Contact: Nutra Pharma Corp. Nina Goldstein 877-895-5647 [email protected] Nutra Pharma Letter to Shareholders Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company. September 25, 2013 - Coral Springs, Florida - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multip |
|
| August 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2013 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| August 15, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR x For Period Ended: June 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Tra |
|
| May 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2013 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| May 15, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ¨Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Transi |
|
| April 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| April 1, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Tr |
|
| December 14, 2012 |
ex99-1 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing |
|
| December 14, 2012 |
Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 12, 2012 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission F |
|
| December 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2012 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. |
|
| December 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2012 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Nam |
|
| December 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2012 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| December 3, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2012 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| November 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2012 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Na |
|
| November 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2012 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| November 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHAR |
|
| November 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| September 12, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2012 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation |
|
| March 19, 2012 | ||
| March 19, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2012 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation or |
|
| March 9, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2012 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation or |
|
| November 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number: 000-32141 CUSIP Number: 67060U 10 9 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For the Fiscal Period Ended September 30, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on |
|
| November 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| August 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2011 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| May 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| April 1, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| January 6, 2011 |
Commission File Number 000-32141 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2010 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Nam |
|
| January 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2010 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name |
|
| January 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2010 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. |
|
| December 21, 2010 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2010 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation |
|
| December 14, 2010 |
Commission File Number 000-32141 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2010 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| November 12, 2010 |
COMMON STOCK PURCHASE WARRANT NUTRA PHARMA CORP. NEITHER THIS SECURITY NOR THE SECURITIES UNDERLYING THIS SECURITY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| November 12, 2010 |
EXECUTION COPY REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of November 8, 2010, by and between NUTRA PHARMA CORP. |
|
| November 12, 2010 |
EXECUTION COPY PURCHASE AGREEMENT PURCHASE AGREEMENT (the ?Agreement?), dated as of November 8, 2010, by and between NUTRA PHARMA CORP. |
|
| November 12, 2010 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2010 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation |
|
| August 18, 2010 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2010 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation o |
|
| August 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2010 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| August 6, 2010 |
Contact: Nutra Pharma Corp. David Isserman 877-895-5647 [email protected] Nutra Pharma Announces Second Quarter 2010 Sales and Distribution Update Nutra Pharma has announced that its over-the-counter (OTC) pain reliever, Cobroxin, has generated sales totaling $150,158 for the quarter ending June 30, 2010 Coral Springs, FL. ? August 6, 2010 - Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology |
|
| August 6, 2010 |
Results of Operations and Financial Condition, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2010 Nutra Pharma Corp. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation or |
|
| May 21, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2010 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| May 18, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number: 000-32141 CUSIP Number: 67060U 10 9 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For the Fiscal Period Ended March 31, 2010 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form |
|
| April 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| April 8, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Amendment No. 2 (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA C |
|
| April 8, 2010 |
Nutra Pharma Corp. 2776 University Drive Coral Springs, Florida 33065 (954) 509-0911 Nutra Pharma Corp. 2776 University Drive Coral Springs, Florida 33065 (954) 509-0911 CORRESPONDENCE FILED VIA EDGAR April 8, 2010 Jim B. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jim Peklank, Staff Accountant Re: Nutra Pharma Corp. (?we? or ?us? or ?our?) Form 10-K for the Fiscal Year Ended December |
|
| February 2, 2010 |
EXHIBIT 99.1 Contact: Nutra Pharma Corp. David Isserman 877-895-5647 [email protected] Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin Nutra Pharma has announced that its over-the-counter (OTC) pain reliever, Cobroxin, has generated sales totaling $583,955 for the fourth quarter ending December 31, 2009. Plantation, FL. ? February 2, 2010 - Nutra |
|
| February 2, 2010 |
Results of Operations and Financial Condition, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2009 Nutra Pharma Corp. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation |
|
| January 25, 2010 |
CORRESPONDENCE FILED VIA EDGAR January 25, 2010 Jim R. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 Washington, D. C. 20549 Attn: Jim Peklend, Staff Accountant Re: Nutra Pharma Corp. Form 10-K for Fiscal Year Ended December 31, 2008 Filed April 15, 2009 Form 10-Q for the quarterly period ended September |
|
| January 25, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Amendment No. 1 (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-32141 NUTRA PHARMA C |
|
| January 25, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Amendment No. 1 (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2009 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Na |
|
| January 13, 2010 |
CORRESPONDENCE FILED VIA EDGAR CORRESPONDENCE FILED VIA EDGAR January 13, 2010 Jim R. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 Washington, D. C. 20549 Attn: Jim Peklenk, Staff Accountant Re: Division of Corporation Finance Correspondence dated December 15, 2009 Nutra Pharma Corp. (the ?Company?), File No. 000-32141 Dear Mr. Rosenb |
|
| December 31, 2009 |
Changes in Registrant's Certifying Accountant U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 18, 2009 Nutra Pharma Corp. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employ |
|
| December 24, 2009 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 18, 2009 Nutra Pharma Corp. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation |
|
| December 24, 2009 |
December 24, 2009 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Nutra Pharma Corp. |
|
| December 16, 2009 |
NUTRA PHARMA CORP. 1537 NW 65th Ave. Plantation, FL 33313 NUTRA PHARMA CORP. 1537 NW 65th Ave. Plantation, FL 33313 FILED VIA EDGAR COURTESY COPY SENT VIA FASCIMILE (202) 772-9291 December 16, 2009 Mr. Jim Peklank Staff Accountant Division of Corporation Finance US Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Division of Corporation Finance Correspondence dated December 15, 2009 to Nutra Pharma Corp. Dear Mr. Peklank: |
|
| November 18, 2009 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Stockholders and Board of Directors ReceptoPharm, Inc. |
|
| November 18, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2008. NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation |
|
| November 18, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2009 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| November 17, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number: 000-32141 CUSIP Number: 67060U 10 9 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For the Quarterly Period Ended September 30, 2009 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report |
|
| October 6, 2009 |
Unregistered Sales of Equity Securities U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2009 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporatio |
|
| August 19, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2009 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| July 29, 2009 |
July 29, 2009 Mr. Rik Deitsch CEO and President Nutra Pharma Corporation Dear Rik, This letter serves as official notification of my resignation as a Director for Nutra Pharma Corporation. My resignation does not relate to any disagreement with Nutra Pharma or its management regarding any matter relating to its operations, policies or practices. It has been a pleasure serving on the Board of Nutra |
|
| July 29, 2009 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2009 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation or |
|
| May 20, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2009 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| April 15, 2009 |
WHOLLY OWNED SUBSIDIARIES OF NUTRA PHARMA CORP. ReceptoPharm, Inc., a Nevada corporation Designer Diagnostics, Inc., a Nevada corporation |
|
| April 15, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name of re |
|
| November 19, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant |
|
| October 3, 2008 |
791 Park of Commerce Blvd. ¨ Suite 300 Boca Raton, Florida 33487 Office (954) 509-0911 ¨ Fax (877) 895-5647 FILED AS CORRESPONDENCE ON EDGAR October 3, 2008 James Rosenberg Senior Assistant Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Allen, Staff Accountant Re: Nutra Pharma Corp, Form 10-KSB-A for the Fiscal Year ended December 31, 2007 (File No. 000-32141) - Amendme |
|
| October 3, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM 10-KSB (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-32141 NUTRA PHA |
|
| September 25, 2008 |
791 Park of Commerce Blvd. ? Suite 300 Boca Raton, Florida 33487 Office (954) 509-0911 ? Fax (877) 895-5647 FILED AS CORRESPONDENCE ON EDGAR September 25, 2008 James Rosenberg Senior Assistant Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Allen, Staff Accountant Re: Nutra Pharma Corp, Form 10-KSB-A for the Fiscal Year ended December 31, 2007 (File No. 000-32141) Dear M |
|
| September 5, 2008 |
Nutra Pharma Corp. 791 Park of Commerce Blvd. Suite 300 Boca Raton, FL 33487 Nutra Pharma Corp. 791 Park of Commerce Blvd. Suite 300 Boca Raton, FL 33487 FILED AS CORRESPONDENCE ON EDGAR September 5, 2008 James Rosenberg Senior Assistant Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Re: Nutra Pharma Corp, Form 10-KSB for the Fiscal Year ended December 31, 2007 (File No. 000-32141) Dear Mr. Rosenberg: This correspondence is in response to your July 21, 2008 cor |
|
| September 5, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-KSB (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-32141 NUTRA PHA |
|
| August 20, 2008 |
CORRESPONDENCE FILED ON EDGAR August 20, 2008 James Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance United States Securities and Exchange Commission Mail Stop 6010 Washington, D. |
|
| August 19, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as s |
|
| August 13, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number: 000-32141 CUSIP Number: 67060U 10 9 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Quarterly Period Ended: June 30, 2008 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form |
|
| May 20, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file numbers 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| May 16, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number: 000-32141 CUSIP Number: 67060U 10 9 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Quarterly Period Ended: March 31, 2008 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form |
|
| April 15, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name of |
|
| April 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2008. NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation or organization |
|
| April 14, 2008 |
Exhibit 99.1 CONTACT: Investor Relations David Isserman 877-895-5647 [email protected] NUTRA PHARMA ACQUIRES REMAINING INTEREST IN BIOPHARMACEUTICAL DRUG DISCOVERY COMPANY - RECEPTOPHARM, INC. Boca Raton, FL. ? April 14, 2008 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that on April 10, 2008, it had acquired th |
|
| April 14, 2008 |
Exhibit 10.1 AGREEMENT AND PLAN OF MERGER This Agreement and Plan of Merger, dated as of this 9th day of April, 2008 (the ?Agreement?), by and among Nutra Pharma Corp., a California corporation (?Nutra Pharma?), NP Acquisition Corporation, a Nevada corporation wholly owned by Nutra Pharma (?Acquisition?), Receptopharm, Inc., a Nevada corporation (?Receptopharm?) and the stockholders of Receptophar |
|
| April 14, 2008 |
Changes in Control of Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2008. NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation or organization |
|
| April 8, 2008 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A-2 Amendment to Form 8-K filed on March 18, 2008 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2008. NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or o |
|
| April 7, 2008 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment to Form 8-K filed on March 18, 2008 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2008. NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or oth |
|
| March 18, 2008 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2008. NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation or organization |
|
| November 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name of registran |
|
| August 17, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| June 25, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Commission file number 000-32141 NUTRA PHARMA CORP. (Name of registrant as specified in its charter) California 91-2021600 (State or Other Jurisdiction of Organization) (IRS Employer Identification 791 Park of Commerce Blvd, Suite 300, Boca Raton, FL 33487 (Addre |
|
| May 21, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name of registrant as |
|
| May 9, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliestevent reported): May 8, 2007 Nutra Pharma Corp. (Exact name of registrant as specified in charter) California (State or other jurisdiction of incorporation) 000-32141 (Commission File Number) 91-202160 |
|
| April 17, 2007 |
PATENT ASSIGNMENT AGREEMENT between NANOLOGIX, INC. and NUTRA PHARMA CORP. Dated , 2006 1 PATENT ASSIGNMENT AGREEMENT This Patent Assignment Agreement (?Agreement?) is dated , 2006 (?Commencement Date?), by and between NanoLogix, Inc., a Delaware corporation having a place of business at 87 Stambaugh Avenue, Suite 2, Sharon, Pennsylvania 16146 (?Assignor?) and Nutra Pharma Corp., a California corp |
|
| April 17, 2007 |
INTERNATIONAL LICENSE AGREEMENT THIS INTERNATIONAL LICENSE AGREEMENT (?Agreement?) is made as of this day of , 2006, ("Effective Date") by and between NanoLogix, Inc. |
|
| April 17, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2006 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name of |
|
| November 14, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2006 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name of registran |
|
| August 21, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2006 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name of registra |
|
| August 21, 2006 |
AMENDED AND RESTATED BYLAWS NUTRA PHARMA, CORP. A California Corporation AMENDED AND RESTATED BYLAWS OF NUTRA PHARMA, CORP. A California Corporation OFFICES 1. PRINCIPAL OFFICE. The principal office for the transaction of the business of the corporation is hereby fixed and located at such place as determined from time to time by the Board of Directors of the Corporation. 2. OTHER OFFICES. Branch or subordinate offices may at any time be established by the Board of Dire |
|
| April 28, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2005 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name |
|
| April 7, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2006 Nutra Pharma Corp. (Exact name of registrant as specified in charter) California 000-32141 91-2021600 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 7, 2006 |
Termination Agreement This Agreement is made by and between Nutra Pharma Corp., a California Corporation (?the Company?), with an address of 3473 High Ridge Road, Boynton Beach, FL 33426 (?the Company?), and Doherty & Company, LLC, a Delaware limited liability company (?Doherty & Company?) and Michael Doherty, an individual (?Doherty?). Doherty & Company, LLC and Doherty are referred to herein ind |
|
| November 22, 2005 |
e10qsb Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 15, 2005 |
OMB Number: 3235-0058 Expires: September 30, 2006 Estimated average burden hours per response. |
|
| November 10, 2005 |
Warrants for the Purchase 10,000,000 Shares of Common Stock NEITHER THE SECURITIES REPRESENTED HEREBY, NOR THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR OTHERWISE DISPOSED OF UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICA |
|
| November 10, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2005 Nutra Pharma Corp. (Exact name of registrant as specified in charter) California (State or other jurisdiction of incorporation) 000-32141 (Commission File Number) 91- |
|
| November 10, 2005 |
Xinhua Financial Network Ltd. 2003-5 Vicwood Plaza 199 Des Voeux Road Central Hong Kong Xinhua Financial Network Ltd. 2003-5 Vicwood Plaza 199 Des Voeux Road Central Hong Kong October 28, 2005 Nutra Pharma Corp. 3473 High Ridge Road Boynton Beach, Florida 33426 Gentlemen: Reference is made to the Agreement, dated September 30, 2005, between Xinhua Financial Network Ltd. (?XFN?) and Nutra Pharma Corp. (the ?Company?). Based upon the foregoing, we are pleased to set forth the terms of |
|
| August 15, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-KSB ? Form 20-F ? Form 11-K x Form 10-QSB ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2005 ? Transition Report on Form 10-KSB ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-QSB ? Transition Repo |
|
| June 6, 2005 |
EXHIBIT 99.2 EXHIBIT A THIS OPTION AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS THERE IS A (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT RELATED THERETO, (II) AN OPINION |
|
| June 6, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2005 Nutra Pharma Corp. (Exact name of registrant as specified in charter) California (State or other jurisdiction of incorporation) 000-32141 (Commission File Number) 91-2021 |
|
| June 6, 2005 |
EXHIBIT 99.3 June 1, 2005 Nutra Pharma Corp. 1829 Corporate Drive Boynton, Florida 33426 Attn: Rik J. Deitsch Ladies and Gentlemen: This letter confirms the retention of Doherty & Company, LLC ("Agent") to act as the sole agent for Nutra Pharma Corp. (the "Company") in connection with the possible private placement or sale of equity, equity-linked or debt securities to one or more third parties (e |
|
| June 6, 2005 |
Exhibit 99.6 June 1, 2005 Board of Directors Nutra Pharma Corporation Members of the Board: Please allow this letter to serve as my resignation as Chairman of the Board of Directors of Nutra Pharma Corporation. Pursuant to the Board Resolution dated today and the contractual obligations therein, I will be stepping down as Chairman as Michael Doherty is named to that position. I will be retaining a |
|
| June 6, 2005 |
EXHIBIT 99.4 June 1, 2005 Nutra Pharma Corp. 1829 Corporate Drive Boynton, Florida 33426 Attn: Rik J. Deitsch Dear Sirs: In connection with our engagement to advise and assist you with the matters set forth in the engagement letter of even date herewith, you and we are entering into this letter agreement. It is understood and agreed that in the event that Doherty & Company LLC ("Doherty") or any o |
|
| June 6, 2005 |
EXHIBIT 99.5 Dr. Michael Flax 2929 University Dr. #102 Coral Springs, FL 33065 June 1, 2005 Rik Deitsch, CEO Nutra Pharma Corporation 1829 Corporate Dr Boynton Beach FL 33426 Dear Mr. Deitsch, This letter shall serve as my resignation from the board of Nutra Pharma Corp with immediate effect. I thank you for the time we have spent together in this exciting company. I am busy in my practice and wit |
|
| June 6, 2005 |
EXHIBIT 99.1 LETTER AGREEMENT This Letter ("Letter"), dated as of June 1, 2005, is executed and delivered by Nutra Pharma Corp. (the "Company"), Doherty & Company, LLC ("Doherty"), a Delaware limited liability company, and Michael Doherty ("Executive"). R E C I T A L S WHEREAS, the Company desires Executive to become the Chairman of the Company, an executive position supervising management of the |
|
| May 26, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2005 ( ) TRANSITION REPORT PURSUANT OF SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period to Commission file number: 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| May 16, 2005 |
OMB Number: 3235-0058 Expires: March 31, 2006 Estimated average burden hours per response. |
|
| May 2, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2004 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-32141 NUTRA PHARMA CORP. (Name |
|
| May 2, 2005 |
Exhibit 10.13 NUTRA PHARMA CORP. 1829 Corporate Drive, Boynton Beach, FL 33426 Office (954) 509-0911 Fax (866) 744-3655 February 14, 2005 Dr. Tan Khandaker 387 Park Avenue South Third floor New York, NY 10016 Dear Dr. Khandaker: Please allow this letter to serve as a mutual Agreement between Nutra Pharma Corporation, a public California Corporation (OTCBB: NPHC) and yourself - Dr. Tan Khandaker, a |
|
| April 12, 2005 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2005 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation or |
|
| March 30, 2005 |
OMB Number: 3235-0058 Expires: March 31, 2006 Estimated average burden hours per response. |
|
| February 24, 2005 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2005 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation |
|
| February 24, 2005 |
Exhibit 16.1 Letter from Eisner LLP pursuant to Item 304(a)(3) of Regulation S-B. Eisner LLP Accountants and Advisors Eisner 750 Third Avenue New York, NY 10017-2703 Tel 212.949.8700 Fax 212.891.4100 www.eisnerllp.com February 24, 2005 United States Securities & Exchange Commission Division of Corporate Finance 450 Fifth Street, N.W. Washington, D.C. 20549 To Whom It May Concern: We have read the |
|
| February 11, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB/A (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2004 ( ) TRANSITION REPORT PURSUANT OF SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period to Commission file number: 000-32141 NUTRA PHARMA CORP. (Exact nam |
|
| February 11, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB/A (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2004 ( ) TRANSITION REPORT PURSUANT OF SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period to Commission file number: 000-32141 NUTRA PHARMA CORP. (Exact na |
|
| January 20, 2005 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 14, 2005 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 000-32141 91-2021600 (State or jurisdiction of (Commission (I.R.S. Employer incorporation |
|
| January 7, 2005 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2004 COMMISSION FILE NUMBER: 000-32141 Nutra Pharma Corp. (Exact name of registrant as specified in its charter) California 91-2021600 (State or jurisdiction of incorporation or o |
|
| January 7, 2005 |
THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "1933 ACT"), NOR REGISTERED UNDER ANY STATE SECURITIES LAW, AND ARE "RESTRICTED SECURITIES" AS THAT TERM IS DEFINED IN RULE 144 UNDER THE 1933 ACT. |
|
| December 21, 2004 |
Exhibit 10.9 SETTLEMENT AGREEMENT AGREEMENT made this 28th day of September, 2004, by and between NUTRA PHARMA CORP., a California corporation ("Nutra Pharma"), and OPUS INTERNATIONAL, LLC., a Maryland limited liability company ("Opus"), provides as follows: In consideration of the mutual promises, covenants, and representations contained herein, and other good and valuable consideration, THE PART |
|
| December 21, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2004 ( ) TRANSITION REPORT PURSUANT OF SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period to Commission file number: 000-32141 NUTRA PHARMA CORP. (Exact |
|
| December 21, 2004 |
Exhibit 10.10 XENACARE Alan Xenakis, MD, ScD, MPH President/CEO 7700 Congress Avenue Suite 3208 Boca Raton, Florida 33487 561-999-0126 To: Rik J. Deitsch, Ph.D. From: Alan P. Xenakis, MD Date: September 28, 2004 RE: Letter of Intent between XenaCare and NutraPharma - - Dear Dr. Deitsch: Thank you for the opportunity to provide Site of Care Investment and Dividend Reinvestment Management Services t |
|
| December 21, 2004 |
Exhibit 10.12 Nutra Pharma Corp. INVESTOR-GATE.COM(R) 18533 Roscoe Blvd #207, Northridge CA 91324 (818) 679-7444 October 8, 2004 Nutra Pharma Corporation Rik J.Deitsch - CEO Dear Mr. Deitsch: This letter agreement (the "Agreement") confirms the terms and conditions of the engagement of INVESTOR-GATE.COM, by Nutra Pharma Corporation (the "Company") to render certain investor relations and financial |
|
| December 21, 2004 |
Exhibit 10.11 Nutra Pharma Corp. AGREEMENT FOR RESEARCH SERVICES THIS AGREEMENT is by and among Nutra Pharma Corp., a California corporation with principal executive offices located at 4001 NW 73rd Way, Coral Springs, Florida 33065 ("Nutra Pharma") and Eno Research and Development, Inc. ("ERDI"), located at P.O. Box 1522, Hillsborough, NC 27278. 1. Terms and Duties Nutra Pharma wishes ERDI to cond |
|
| November 15, 2004 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2004 COMMISSION FILE NUMBER: 000-50955 NUTRA PHARMA CORP. (Exact name of registrant as specified in its charter) California 91-2021600 - - (State or jurisdiction of incorporation |
|
| October 4, 2004 |
Table of Contents Exhibit 17.11 Resignation of Dr. Soram Singh Khalsa RESIGNATION OF DR. SORAM SINGH KHALSA Soram Singh Khalsa SORAM SINGH KHALSA Exhibit 17.11 Resignation of Dr. Soram Singh Khalsa RESIGNATION OF DR. SORAM SINGH KHALSA I, DR. SORAM SINGH KHALSA, hereby resign as a director of NUTRA PHARMA CORP., effective September 28, 2004. Date: September 28, 2004 Soram Singh Khalsa SORAM SINGH |
|
| October 4, 2004 |
Table of Contents Exhibit 17.12 Resignation of David C. McClelland RESIGNATION OF DAVID C. MCCLELLAND David C. McClelland DAVID C. MCCLELLAND Exhibit 17.12 Resignation of David C. McClelland RESIGNATION OF DAVID C. MCCLELLAND I, DAVID C. MCCLELLAND, hereby resign as a director of NUTRA PHARMA CORP., effective September 28, 2004. Date: September 28, 2004 David C. McClelland DAVID C. MCCLELLAND |
|
| October 4, 2004 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2004 COMMISSION FILE NUMBER: 000-32141 Nutra Pharma Corp. (Exact name of registrant as specified in its charter) California 91-2021600 State or jurisdiction of incorporation (IRS |
|
| October 4, 2004 |
Exhibit 17.10 Resignation of Dr. Mitchell Felder RESIGNATION OF DR. MITCHELL FELDER I, DR. MITCHELL FELDER, hereby resign as a director of NUTRA PHARMA CORP., effective September 28, 2004. Date: September 28, 2004 Table of Contents Mitchell Felder Mitchell Felder MITCHELL FELDER |
|
| August 27, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2004 ( ) TRANSITION REPORT PURSUANT OF SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period to Commission file number: 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| August 16, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING COMMISSION FILE NUMBER 000-32141 CUSIP 67060U 10 9 (Check One): [ ]Form 10-KSB []Form 11-K [X]Form 10-QSB []Form N-SAR For Period Ended: JUNE 30, 2004 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N-SAR For the Transition Period Ended: Read attached instruction sheet before preparing form. |
|
| May 26, 2004 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Nutra Pharma Corp. on Form 10-QSB for the period ending March 31, 2004, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Rik J. Deitsch, Chief Executive Officer and Chief Financial Of |
|
| May 26, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2004 ( ) TRANSITION REPORT PURSUANT OF SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period to Commission file number: 000-32141 NUTRA PHARMA CORP. (Exact name |
|
| May 26, 2004 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER Exhibit 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER I, Rik J. Deitsch, certify that: 1. I have reviewed this report on Form 10-QSB of Nutra Pharma Corp.; 2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such sta |
|
| May 17, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Expires: May 15, 2006 NOTIFICATION OF LATE FILING (CHECK ONE): / /Form 10-K / /Form 20-F / /Form 11-K /x /Form 10-QSB/ /Form N-SAR hours per For the Quarter ended: March 31, 2004 / / Transition Report on Form 10-K / / Transition Report on Form 20-F / / Transition Report on Form 11-K / / Transition Report on Form 10 |
|
| May 7, 2004 |
Code of Ethics (incorporated by reference from Report on Form 10-K/A filed on May 7, 2004). Exhibit 14.1 NUTRA PHARMA CORP. CODE OF ETHICS 1. Compliance With Law All employees, officers and directors of the Company should respect and comply with all of the laws, rules and regulations of the U.S. and other countries, and the states, counties, cities and other jurisdictions, in which the Company conducts its business or the laws, rules and regulations of which are applicable to the Company |
|
| May 7, 2004 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER Exhibit 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER I, Rik J. Deitsch, certify that: 1. I have reviewed this report on Form 10KSB/A of Nutra Pharma Corp.; 2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such st |
|
| May 7, 2004 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A Amendment No. 1 10KSB/A 1 form10ksbamay7.htm DECEMBER 31, 2003 10K AMENDMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A Amendment No. 1 (Mark One) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003 ( ) TRANSITION REPORT PURSUANT OF SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period to Comm |
|
| May 7, 2004 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Nutra Pharma Corp. on Form 10KSB/A for the period ending December 31, 2003, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Rik J. Deitsch, Chief Executive Officer and Chief Financial O |
|
| April 20, 2004 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003 ( ) TRANSITION REPORT PURSUANT OF SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period to Commission file number: 000-32141 NUTRA PHARMA CORP. (Exact name of registrant as s |
|
| April 20, 2004 |
Exhibit 20.4 Amendment to License Agreement by and between Biotherapeutics, Inc. and Nutra Pharma Corp. dated November 11, 2003 AMENDMENT TO LICENSE AGREEMENT This amendment is made and entered into on the 11th day of November, 2003, by and between Biotherapeutics, Inc., a Florida corporation having a principal place of business at 1350 NW 69th Avenue, Suite One, Plantation, FL, hereinafter referr |
|
| April 20, 2004 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Nutra Pharma Corp. on Form 10KSB for the period ending December 31, 2003, as filed with the Securities and Exchange Commission on the date hereof (the "Report'), I, Rik Deitsch, Chief Executive Officer and Chief Financial Office |
|
| April 20, 2004 |
CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION OF NUTRA PHARMA CORP. A California corporation Exhibit 3.3 Amendment to Articles of Incorporation dated October 30, 2001 CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION OF NUTRA PHARMA CORP. A California corporation The undersigned hereby certifies as follows: ONE: That they are the President and Secretary, respectively, of NUTRA PHARMA CORP., a California corporation. TWO: That, at a meeting of the Board of Directors on October 16, 2001 |
|
| April 20, 2004 |
Exhibit 20.3 License Agreement dated October 3, 2003 between Biotherapeutics, Inc. and Nutra Pharma Corp. LICENSE AGREEMENT This agreement is made and entered into on the 3rd day of October, 2003, by and between Biotherapeutics, Inc., a Florida corporation having a principal place of business at 1850 NW 69th Avenue, Suite One, Plantation, FL, hereinafter referred to as LICENSOR and Nutra Pharma Co |
|
| April 20, 2004 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Rik Deitsch, certify that: 1. I have reviewed this report on Form 10KSB of Nutra Pharma Corp.; 2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in l |
